Cargando…

The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1

Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein...

Descripción completa

Detalles Bibliográficos
Autores principales: Ciccone, Lidia, Shi, Chenghui, di Lorenzo, Davide, Van Baelen, Anne-Cécile, Tonali, Nicolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288020/
https://www.ncbi.nlm.nih.gov/pubmed/32456156
http://dx.doi.org/10.3390/molecules25102439
_version_ 1783545183348981760
author Ciccone, Lidia
Shi, Chenghui
di Lorenzo, Davide
Van Baelen, Anne-Cécile
Tonali, Nicolo
author_facet Ciccone, Lidia
Shi, Chenghui
di Lorenzo, Davide
Van Baelen, Anne-Cécile
Tonali, Nicolo
author_sort Ciccone, Lidia
collection PubMed
description Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein interactions. Amyloid aggregates usually contain not only single type of amyloid protein, but also other type of proteins and this phenomenon can be rationally explained by the process of protein cross-seeding and co-assembly. Amyloid cross-interaction is ubiquitous in amyloid fibril formation and so a better knowledge of the amyloid interactome could help to further understand the mechanisms of amyloid related diseases. In this review, we discuss about the cross-interactions of amyloid-β peptides, and in particular Aβ1-42, with other amyloids, which have been presented either as integrated part of Aβ neurotoxicity process (such as Tau) or conversely with a preventive role in AD pathogenesis by directly binding to Aβ (such as transthyretin, cystatin C and apolipoprotein A1). Particularly, we will focus on all the possible therapeutic strategies aiming to rescue the Aβ toxicity by taking inspiration from these protein-protein interactions.
format Online
Article
Text
id pubmed-7288020
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-72880202020-06-15 The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1 Ciccone, Lidia Shi, Chenghui di Lorenzo, Davide Van Baelen, Anne-Cécile Tonali, Nicolo Molecules Review Alzheimer’s disease (AD) represents a progressive amyloidogenic disorder whose advancement is widely recognized to be connected to amyloid-β peptides and Tau aggregation. However, several other processes likely contribute to the development of AD and some of them might be related to protein-protein interactions. Amyloid aggregates usually contain not only single type of amyloid protein, but also other type of proteins and this phenomenon can be rationally explained by the process of protein cross-seeding and co-assembly. Amyloid cross-interaction is ubiquitous in amyloid fibril formation and so a better knowledge of the amyloid interactome could help to further understand the mechanisms of amyloid related diseases. In this review, we discuss about the cross-interactions of amyloid-β peptides, and in particular Aβ1-42, with other amyloids, which have been presented either as integrated part of Aβ neurotoxicity process (such as Tau) or conversely with a preventive role in AD pathogenesis by directly binding to Aβ (such as transthyretin, cystatin C and apolipoprotein A1). Particularly, we will focus on all the possible therapeutic strategies aiming to rescue the Aβ toxicity by taking inspiration from these protein-protein interactions. MDPI 2020-05-23 /pmc/articles/PMC7288020/ /pubmed/32456156 http://dx.doi.org/10.3390/molecules25102439 Text en © 2020 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).
spellingShingle Review
Ciccone, Lidia
Shi, Chenghui
di Lorenzo, Davide
Van Baelen, Anne-Cécile
Tonali, Nicolo
The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
title The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
title_full The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
title_fullStr The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
title_full_unstemmed The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
title_short The Positive Side of the Alzheimer’s Disease Amyloid Cross-Interactions: The Case of the Aβ 1-42 Peptide with Tau, TTR, CysC, and ApoA1
title_sort positive side of the alzheimer’s disease amyloid cross-interactions: the case of the aβ 1-42 peptide with tau, ttr, cysc, and apoa1
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7288020/
https://www.ncbi.nlm.nih.gov/pubmed/32456156
http://dx.doi.org/10.3390/molecules25102439
work_keys_str_mv AT cicconelidia thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT shichenghui thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT dilorenzodavide thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT vanbaelenannececile thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT tonalinicolo thepositivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT cicconelidia positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT shichenghui positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT dilorenzodavide positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT vanbaelenannececile positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1
AT tonalinicolo positivesideofthealzheimersdiseaseamyloidcrossinteractionsthecaseoftheab142peptidewithtauttrcyscandapoa1